Working forward from that, and applying the timescales UK regulators and NICE typically take, the realistic sequence looks like this
Some people transition to a lower maintenance dose instead of stopping completely
In men, significant weight loss from these agents may improve obesity-related hypogonadism, testosterone levels, and cardiovascular risk factors
Lewerenz J, Maher P, Methner A
Ohashi K, Ishikawa T, Hoshii A, Hokari T, Suzuki M, Noguchi H, Hirosawa H, Koyama F, Kobayashi M, Hirosawa S, et al
A 2024 Reuters analysis by Prime Therapeutics (a large PBM) reported that in the first two years after introduction, patients on weight-loss GLP-1s actually had higher total annual healthcare costs than matched controls (driven by drug costs and some medical utilization) ( [42] )